IN8bio, Inc. Banner Image

IN8bio, Inc.

  • Ticker INAB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
IN8bio, Inc. Logo Image
  • 11-50 Employees
  • Based in New York City, New York
IN8bio Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio developsMore ex vivo-expanded and activated gamma-delta T cell based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering and cell-type specific manufacturing capabilities, which they refer to collectively as their DeltEx platform. IN8bio’s platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic.
5.0 / 5.0 (1)

IN8bio, Inc. reports have an aggregate usefulness score of 5.0 based on 1 reviews.

IN8bio, Inc.

Most Recent Annual Report

IN8bio, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

IN8bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!